|
1
|
Baba H, Kuwabara K, Ishiguro T, Kumamoto
K, Kumagai Y, Ishibashi K, Haga N and Ishida H: Prognostic factors
for stage IV gastric cancer. Int Surg. 98:181–187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou
S, Ding J and Wu K: Bird's-eye view on gastric cancer research of
the past 25 years. J Gastroenterol Hepatol. 20:360–365. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fodale V, Pierobon M, Liotta L and
Petricoin E: Mechanism of cell adaptation: When and how do cancer
cells develop chemore-sistance? Cancer J. 17:89–95. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dai Z, Huang Y and Sadée W: Growth factor
signaling and resistance to cancer chemotherapy. Curr Top Med Chem.
4:1347–1356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng T, Wang J, Chen X and Liu L: Role of
microRNA in anticancer drug resistance. Int J Cancer. 126:2–10.
2010. View Article : Google Scholar
|
|
9
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar
|
|
10
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
An Y, Zhang Z, Shang Y, Jiang X, Dong J,
Yu P, Nie Y and Zhao Q: miR-23b-3p regulates the chemoresistance of
gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis.
6:e17662015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar
|
|
14
|
Patnaik SK, Yendamuri S, Kannisto E,
Kucharczuk JC, Singhal S and Vachani A: MicroRNA expression
profiles of whole blood in lung adenocarcinoma. PLoS One.
7:e460452012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen W, Tang Z, Sun Y, Zhang Y, Wang X,
Shen Z, Liu F and Qin X: miRNA expression profile in primary
gastric cancers and paired lymph node metastases indicates that
miR-10a plays a role in metastasis from primary gastric cancer to
lymph nodes. Exp Ther Med. 3:351–356. 2012.PubMed/NCBI
|
|
16
|
Yasui W, Sentani K, Sakamoto N, Anami K,
Naito Y and Oue N: Molecular pathology of gastric cancer: Research
and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu D, Xiao Z, Wang W, Xu Y, Gao S, Deng L,
He W, Yang Y, Guo X and Wang X: Down regulation of CIAPIN1 reverses
multidrug resistance in human breast cancer cells by inhibiting
MDR1. Molecules. 17:7595–7611. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rebucci M and Michiels C: Molecular
aspects of cancer cell resistance to chemotherapy. Biochem
Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Butler EB, Zhao Y, Muñoz-Pinedo C, Lu J
and Tan M: Stalling the engine of resistance: Targeting cancer
metabolism to overcome therapeutic resistance. Cancer Res.
73:2709–2717. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
|
|
23
|
Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y
and Fan D: Methylation of miR-129–5p CpG island modulates
multi-drug resistance in gastric cancer by targeting ABC
transporters. Oncotarget. 5:11552–11563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li
K, Zhou L, Sun Y, Li M, Zhou J, et al: miR-508–5p regulates
multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene. 33:3267–3276. 2014. View Article : Google Scholar
|
|
25
|
Wang Y, Gu X, Li Z, Xiang J, Jiang J and
Chen Z: microRNA expression profiling in multidrug resistance of
the 5-FU-induced SGC-7901 human gastric cancer cell line. Mol Med
Rep. 7:1506–1510. 2013.PubMed/NCBI
|
|
26
|
Bordeleau ME, Robert F, Gerard B,
Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco
JA Jr, et al: Therapeutic suppression of translation initiation
modulates chemosensitivity in a mouse lymphoma model. J Clin
Invest. 118:2651–2660. 2008.PubMed/NCBI
|
|
27
|
Hagner PR, Schneider A and Gartenhaus RB:
Targeting the translational machinery as a novel treatment strategy
for hematologic malignancies. Blood. 115:2127–2135. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Svitkin YV, Pause A, Haghighat A, Pyronnet
S, Witherell G, Belsham GJ and Sonenberg N: The requirement for
eukaryotic initiation factor 4A (elF4A) in translation is in direct
proportion to the degree of mRNA 5′ secondary structure. RNA.
7:382–394. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shuda M, Kondoh N, Tanaka K, Ryo A,
Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, et al:
Enhanced expression of translation factor mRNAs in hepatocellular
carcinoma. Anticancer Res. 20:2489–2494. 2000.PubMed/NCBI
|
|
30
|
Eberle J, Krasagakis K and Orfanos CE:
Translation initiation factor eIF-4A1 mRNA is consistently
overexpressed in human melanoma cells in vitro. Int J Cancer.
71:396–401. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Modelska A, Turro E, Russell R, Beaton J,
Sbarrato T, Spriggs K, Miller J, Gräf S, Provenzano E, Blows F, et
al: The malignant phenotype in breast cancer is driven by
eIF4A1-mediated changes in the translational landscape. Cell Death
Dis. 6:e16032015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lankat-Buttgereit B and Göke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S,
Long X, Jiang Q, Song Y, Cheng C, et al: Tumor suppressor PDCD4
modulates miR-184-mediated direct suppression of C-MYC and BCL2
blocking cell growth and survival in nasopharyngeal carcinoma. Cell
Death Dis. 4:e8722013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin
P, Fan Z and Li Q: COX-2 contributes to P-glycoprotein-mediated
multidrug resistance via phosphorylation of c-Jun at Ser63/73 in
colorectal cancer. Carcinogenesis. 32:667–675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu Y, Lin Y, Yang Z, Yang G, Li G, Liu Y,
Tan X, Huang Y, Wu X, Wang Y, et al: FBXW7 overexpression
suppresses renal cancer cell proliferation and induces apoptosis.
Med Oncol. 32:2152015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Juin P, Hueber AO, Littlewood T and Evan
G: c-Myc-induced sensitization to apoptosis is mediated through
cytochrome c release. Genes Dev. 13:1367–1381. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu L, Tanimoto A, Murata Y, Sasaguri T,
Fan J, Sasaguri Y and Watanabe T: Matrix metalloproteinase-12 gene
expression in human vascular smooth muscle cells. Genes Cells.
8:225–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie S, Issa R, Sukkar MB, Oltmanns U,
Bhavsar PK, Papi A, Caramori G, Adcock I and Chung KF: Induction
and regulation of matrix metalloproteinase-12 in human airway
smooth muscle cells. Respir Res. 6:1482005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hofmann HS, Hansen G, Richter G, Taege C,
Simm A, Silber RE and Burdach S: Matrix metalloproteinase-12
expression correlates with local recurrence and metastatic disease
in non-small cell lung cancer patients. Clin Cancer Res.
11:1086–1092. 2005.PubMed/NCBI
|
|
40
|
Kim JM, Kim HJ, Koo BS, Rha KS and Yoon
YH: Expression of matrix metalloproteinase-12 is correlated with
extracapsular spread of tumor from nodes with metastasis in head
and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol.
270:1137–1142. 2013. View Article : Google Scholar
|
|
41
|
Lv FZ, Wang JL, Wu Y, Chen HF and Shen XY:
Knockdown of MMP12 inhibits the growth and invasion of lung
adeno-carcinoma cells. Int J Immunopathol Pharmacol. 28:77–84.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Toft DJ, Rosenberg SB, Bergers G, Volpert
O and Linzer DI: Reactivation of proliferin gene expression is
associated with increased angiogenesis in a cell culture model of
fibrosarcoma tumor progression. Proc Natl Acad Sci USA.
98:13055–13059. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Shaughnessy J: Extending survival with
chemotherapy in metastatic breast cancer. Oncologist. 10(Suppl 3):
20–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
